Data as of Dec 06
| -0.12 / -4.56%|
CytRx Corp. is a biopharmaceutical research and development company specializes in oncology. Its pipeline includes three programs in clinical development for cancer indications: INNO-206, Tamibarotene and Bafetinib. The company has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, and has initiated a Phase 2 trial for patients with advanced pancreatic ductual adenocarcinomas. Its pipeline also includes tamibarotene, which it is testing in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer, and which is in a Phase 2 clinical trial as a treatment for acute promyelocytic leukemia. The Company completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia, and plans to seek a partner for further development of bafetinib. CytRx was founded in 1985 and is headquartered in Los Angeles, CA.
|Steven A. Kriegsman||President, Chief Executive Officer & Director|
|John Y. Caloz||Chief Financial Officer & Treasurer|
|Daniel J. Levitt||Chief Medical Officer & Executive Vice President|
|David J. Haen||VP-Business Development & Head-Investor Relations|
|Douglas Scott Wieland||Senior Vice President-Drug Development|